Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: Rituximab-pvvr, Abatacept, Sterile Sodium Chloride; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 17
States / cities: Orange, California • Palo Alto, California • San Francisco, California + 14 more

Conditions: Type 2 Diabetes Mellitus, High Blood Sugar
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Coronary Artery Disease
Interventions: PROMUS Element Coronary Stent System, Aspirin, Thienopyridine; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 21
States / cities: La Jolla, California • Sacramento, California • San Diego, California + 17 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, IMGN632, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 13
States / cities: Duarte, California • Orange, California • Tampa, Florida + 10 more

Conditions: Healthy
Interventions: Calderasib, PPI; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Postmenopausal Osteoporosis
Interventions: risedronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 923 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Birmingham, Alabama • Oakland, California • San Diego, California + 16 more

Conditions: Healthy
Interventions: Sumatriptan Succinate, Imitrex®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: AML
Interventions: Venetoclax, CC-486; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: LY3410738, Esomeprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Glaucoma, Ocular Hypertension
Interventions: INO-8875, Placebo; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: V118E, PREVNAR 20™, Saline; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Hallandale, Florida • South Miami, Florida • Springfield, Missouri + 1 more

Conditions: 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
Interventions: Administration of AZD6738; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: La Jolla, California

Conditions: HIV Infections
Interventions: nevirapine IR, nevirapine XR; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,068 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 30 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV vaccine GSK3003895A (formulation 1), RSV vaccine GSK3003898A (formulation 2), RSV vaccine GSK3003899A (formulation 3), Boostrix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Mesa, Arizona • San Diego, California • Lenexa, Kansas + 4 more

Conditions: Sunscreening Agents
Interventions: Sunscreening Sport Spray Rest (BAY987519), Untreated skin; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Vaccination, Skin Absorption
Interventions: Microneedle Formulation 1, Microneedle Formulation 2; Device
Lead sponsor: Emory University; Other
Eligibility: 6 Weeks to 24 Months
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: TRV734; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Lennox Gastaut Syndrome
Interventions: Carisbamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Baltimore, Maryland • Lebanon, New Hampshire • Durham, North Carolina + 4 more

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Interventions: liothyronine, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
Interventions: TAVT-45, Zytiga, Prednisone; Drug
Lead sponsor: Tavanta Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin suspension, Lipitor; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: GB-102, Aflibercept; Drug
Lead sponsor: Graybug Vision; Industry
Eligibility: 50 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more

Conditions: Hallux Valgus
Interventions: TLC590, Naropin®, Normal Saline, Bupivacaine; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more

Search by objective public record fields.

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions

CC-486 and Venetoclax for Acute Myeloid Leukemia

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

A Study of V118E in Healthy Participants (V118E-003)

AZD6738 First Time in Patient Multiple Ascending Dose Study

VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

18850 - Human Photoallergy Test

Microneedle Patch Study in Healthy Infants/Young Children

A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

Developing Oral LT3 Therapy for Heart Failure - HFpEF

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Bioavailability Study for New Atorvastatin Formulation

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy